TheraRadar
Landscape / Oncology
Page updated Jul 4, 2026 · using data updated on Jun 28, 2026

Hepatocellular Carcinoma Clinical Trial Landscape

Hepatocellular carcinoma (HCC) is the most common type of liver cancer, primarily affecting individuals with underlying liver diseases such as cirrhosis. As a significant area of oncological research, the clinical trial landscape for HCC is robust, with 1,383 trials registered since 2008.

Currently, 616 trials are actively recruiting, enrolling, or active but not recruiting patients. The majority of active trials are in Phase 2 (390 trials), followed by Phase 1 (214 trials), suggesting a strong focus on early-stage drug development and investigation of novel therapeutic approaches.

Phase 3 trials account for 91 active studies, while Phase 4 trials represent 24 active studies. AstraZeneca leads industry sponsorship with 12 active trials, followed by Roche and Akeso, each with 6 active trials.

Shanghai Henlius Biotech and AbbVie are also notable sponsors, each with 4 active trials. The higher number of Phase 2 trials compared to Phase 3 and 4 suggests a dynamic but still maturing clinical pipeline for HCC.

Trial activity

626 active / 1,407 total since 2008
Active by phase 93 Ph3 / 216 374 Ph2 / 817 133 Ph1 / 315 26 Ph4 / 59

Competitive Intelligence

This Hepatocellular Carcinoma competitive landscape maps 14 companies against 15 mechanisms of action (MOA) across 26 active drug-development programs, including 9 with a confirmed FDA PDUFA date. Each cell is the lead program for a company–mechanism pair — its trial phase, modality, combination, and nearest readout. Read down a column to see who is competing on the same mechanism in Hepatocellular Carcinoma, across a row to see one company's mechanistic spread, and click any cell for the full program list and trial links.

Beta 14 companies 15 mechanisms 26 programs mapped 9 lowTrust (35%) 9 ⚖ PDUFA-dated ⏰ 10 due ≤6 mo click any cell → asset tearsheet
At a glance

Hepatocellular Carcinoma shows 26 programs across 14 companies and 15 mechanisms. The most contested mechanism is Multikinase (VEGFR) (7 programs).

Key findings
  • 83% of Multikinase (VEGFR) programs (10 of 12) are combos with novel agents — class-extension work, not class-validation.
  • Top 3 mechanisms (Multikinase (VEGFR), GPC3, PD-L1 / VEGF-A bispecific antibody) account for ~22% of programs — class concentration is low.
  • AstraZeneca runs 10 programs — the deepest pipeline in this view.
  • 18 hot readouts in next 6 months — most imminent: Bristol-Myers Squibb (Multikinase (VEGFR), CheckMate 9DW).
  • 28 trials are stale (overdue without status change) — possible class-maturity inflection or operational issue.
  • 47 single-program mechanisms in the long tail — 19 are Ph2+ first-in-class first-mover bets.
  • 39 NME candidates in the long tail.
  • Most-novel-of-novel: Chengdu New Radiomedicine Technology 90Y microspheres (Ph3) — first-in-class within scope + NME candidate.

Forward catalysts next 18 months⏰ 10 due ≤6 mo⚖ 9 PDUFA-dated

Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.

Company × Mechanism

Each cell = a company’s most-advanced program in that mechanism. Click for the asset tearsheet.
Unverified (lowTrust) cells:
Ph1 Ph2 Ph3 Ph4 ⚠ lowTrust +combo
Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →
Multikinase (VEGFR)
Anti-VEGF (bevacizumab)
CTLA-4
VEGFA
GARP:TGF-β1 complex antibody
PD-L1 / VEGF-A bispecific antibody
VEGFR
TIGIT
PD-1 / VEGF bispecific
PD-1 (nivolumab)
CTLA-4 (Hengrui)
AFP-targeting CAR-T
TCR
GPC3
Hypoxia-activated prodrug
AstraZeneca
Roche / Genentech
🇨🇳Akeso
AbbVie
Bristol-Myers Squibb
🇨🇳Suzhou Suncadia Biopharmaceut…
Biotheus
Chia Tai Tianqing Pharmaceuti…
Eureka
Lion TCR Pte.
Teclison
Eisai
🇨🇳Jiangsu HengRui Medicine
🇨🇳Shanghai Henlius

Phase 3 leaders · most advanced

  1. active University of Birmingham NCT03017326
  2. recruiting AstraZeneca NCT06921785
  3. active NRG Oncology NCT03186898
  4. recruiting NRG Oncology NCT07166406
  5. recruiting Suzhou Suncadia Biopharmaceuticals Co., Ltd. NCT06618664

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

Single-company mechanisms — BD white space 9 found

Mechanisms only ONE company is pursuing in this indication — the uncrowded / first-in-class bets the matrix cap hides. ⚡ first-in-class · ⚠ unverified mechanism. ⚡ first-in-class is computed across 61 mapped landscapes — scope-limited, not a global claim.
⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 61 mapped landscapes
Single-program mechanisms (47) — one program each — earliest-stage, sorted by phase
PhaseMechanismCompanyModalityReadoutTrial
Ph3 90Y microspheres ⚡ 🌱 🆕 ⚙️ Chengdu New Radiomedicine… 4Q27 NCT06900543
Ph3 A3AR ⚡ 🌱 🆕 Can-Fite BioPharma 1Q26 NCT05201404
Ph3 Anti-PD-1 / VEGFR2 inhibitor ⚡ 🌱 🆕 ⚙️ Jiangsu HengRui Medicine IV ⏰ 3Q26 NCT05320692
Ph3 ARGININE DEIMINASE 🌱 🆕 Polaris Group 3Q28 NCT05317819
Ph3 CTLA-4 inhibitor ⚡ 🌱 AstraZeneca IV ⏰ 3Q26 NCT05557838
Ph3 IL-6/JAK/STAT3 inhibitor ⚡ 🌱 🆕 ⚙️ Beijing Shenogen Biomedic… Oral 3Q25 NCT05594927
Ph2+Ph3 Multi-kinase (regorafenib) 🌱 Nanjing Sanhome IV 1Q30 NCT07392866
Ph3 PD-1 / TIGIT bispecific 🌱 🆕 AstraZeneca IV 1Q29 NCT06921785
Ph3 PD-1 × CTLA-4 bispecific 🌱 🆕 ⚙️ Akeso 1Q26 NCT05489289
Ph3 PROGESTERONE RECEPTOR 🌱 Changchun GeneScience 2Q27 NCT07356037
Ph2+Ph3 Therapeutic HBV vaccine ⚡ 🌱 🆕 ⚙️ Guangzhou Virotech IV 4Q28 NCT07589244
Ph2 AKR1C3 ⚡ 🌱 Zhejiang Hisun Oral 4Q27 NCT07310173
Ph1+Ph2 Anti-Angiopoietin-2 ⚡ 🌱 🆕 ⚙️ TCM ⏰ 3Q26 NCT03812874
Ph1+Ph2 Anti-CD73 ⚡ 🌱 🆕 ⚙️ Lepu Biopharma 2Q28 NCT07479485
Ph1+Ph2 Anti-FGF19 (mAb) ⚡ 🌱 🆕 ⚙️ Huahui Health 4Q28 NCT07547553
Ph2 Autologous T-cell (Rapa) 🌱 🆕 ⚙️ Lukas Biomedical ⏰ 4Q26 NCT05304481
Ph2 B7-H3 ADC 🌱 🆕 Daiichi Sankyo 3Q28 NCT06330064
Ph2 DNA plasmid vaccine ⚡ 🌱 🆕 ⚙️ Newish Technology (Beijin… 4Q28 NCT07324304
Ph2 FGFR4 inhibitor ⚡ 🌱 🆕 ⚙️ Abbisko 2Q27 NCT07327034
Ph1+Ph2 GPC3 CAR-T ⚡ 🌱 🆕 ⚙️ OriCell ⏰ 4Q26 NCT05652920
Ph1+Ph2 GPC3 radioligand ⚡ 🌱 🆕 ⚙️ Bristol-Myers Squibb 2Q30 NCT06726161
Ph1+Ph2 GPRC5D-targeting agent ⚡ 🌱 🆕 ⚙️ AstraZeneca SC 1Q28 NCT06795022
Ph1+Ph2 HBsAg-specific CAR-T ⚡ 🌱 🆕 ⚙️ SCG Cell Therapy Pte. 3Q25 NCT05417932
Ph2 LAG-3 🌱 🆕 Regeneron IV 1Q25 NCT03916627
Ph1+Ph2 Oncolytic HSV-1 (IL-12/15/PD-L1) ⚡ 🌱 🆕 ⚙️ CNBG-Virogin IV 4Q25 NCT06124001
Ph1+Ph2 PD-1 × VEGF bispecific 🌱 🆕 Pfizer IV 4Q27 NCT07227012
Ph2 PD-L1 (durvalumab) 🌱 Boston Scientific Corpora… IV 2Q27 NCT05063565
Ph2 PD-L1 ADC 🌱 🆕 Shanghai Henlius ⏰ 4Q26 NCT06742892
Ph1+Ph2 STAT3 ⚡ 🌱 🆕 Tvardi Therapeutics, Inco… IV 1Q27 NCT05440708
Ph2 VEGFR2 🌱 GrandPharma (China) IV 4Q27 NCT07334483
Ph1+Ph2 WNT ⚡ 🌱 Iterion Oral ⏰ 2Q26 NCT05797805
Ph1 AFP-specific TCR-T cell ⚡ 🌱 🆕 ⚙️ Shanghai Ruiliyuan ⏰ 3Q26 NCT06515314
Ph1 Anti-SIGNAL (mAb) 🌱 🆕 Boehringer Ingelheim IV 3Q24 NCT05249426
Ph1 BCAT ⚡ 🌱 🆕 Alnylam IV 3Q27 NCT06600321
Ph1 c-Met inhibitor ⚡ 🌱 🆕 ⚙️ Lee's Pharmaceutical Limi… Oral 4Q25 NCT06374485
Ph1 CBP/β-catenin inhibitor 🌱 🆕 ⚙️ Eisai 1Q27 NCT03833700
Ph1 Claudin-6 ADC 🌱 🆕 ⚙️ Bayer 3Q29 NCT06764316
Ph1 DLK1 🌱 🆕 Chiome Bioscience 2Q27 NCT06636435
Ph1 FK506-binding protein 1A inhibitor ⚡ 🌱 Captor 2Q29 NCT06994572
Ph1 IL-6R ⚡ 🌱 🆕 Roche / Genentech IV 4Q25 NCT05022927
Ph1 MAGE-A1 × CD3 bispecific 🌱 🆕 ⚙️ Corregene 1Q30 NCT07583316
Ph1 Oncolytic virus 🌱 🆕 ⚙️ Binhui Biopharmaceutical 3Q25 NCT05698459
Ph1 SHP2 inhibitor 🌱 🆕 ⚙️ Shanghai Fosun Pharmaceut… 2Q30 NCT07558200
Ph1 TCR-T cell therapy ⚡ 🌱 🆕 ⚙️ SCG Cell Therapy Pte. 4Q25 NCT06617000
Ph1 TYROSINE KINASE ⚡ 🌱 🆕 Etnova 1Q27 NCT06326502
Ph1 Undisclosed target 🌱 🆕 Zymeworks BC 3Q27 NCT07164313
Ph1 Wnt/β-catenin inhibitor ⚡ 🌱 🆕 ⚙️ Eisai 1Q27 NCT03264664
Emerging & small-cap sponsors (12) — few programs here — partnering / M&A radar
PhaseMechanismCompanyModalityReadoutTrial
Ph1 GPC3 Aptamer Sciences 4Q27 NCT06687941
Ph1 GPC3 BeOne Medicines IV 2Q28 NCT06427941
Ph1 GPC3 CARsgen Cell therapy ⏰ 4Q26 NCT06560827
Ph2 Multikinase (VEGFR) CatalYm IV 3Q29 NCT07219459
Ph1+Ph2 Multikinase (VEGFR) CSPC ZhongQi Pharmaceutic… IV 2Q28 NCT07282509
Ph3 🇨🇳 Multikinase (VEGFR) CStone Oral 2Q25 NCT04194775
Ph2 PD-L1 / VEGF-A bispecific antibody DualityBio 2Q30 NCT06953089
Ph1 🇨🇳 GPC3 Guangzhou FineImmune Cell therapy 2Q28 NCT07493044
Ph1 GPC3 Myeloid IV 4Q27 NCT06478693
Ph2+Ph3 🇨🇳 Multikinase (VEGFR) Shandong New Time Oral 3Q25 NCT05408221
Ph2 🇨🇳 Multikinase (VEGFR) Zhejiang Haichang IV ⏰ 4Q26 NCT06309485
Ph2+Ph3 🇨🇳 Hypoxia-activated prodrug Zhejiang Raygene 2Q29 NCT06844357
Unclassified programs (27) — mechanism not captured yet
PhaseMechanismCompanyModalityReadoutTrial
Ph2+Ph3 Bevacizumab, Capecitabine, Oxaliplatinunclassified Innovent Biopharmaceutica… NCT07490262
Ph3 MANDARIN (S6371)unclassified Boston Scientific Corpora… NCT05016245
Ph3 TPST-1120, Atezolizumab, Bevacizumabunclassified Tempest Therapeutics NCT06680258
Ph3 HLX13, US-sourced YERVOY®, EU-sourced YERVOY®unclassified Shanghai Henlius Biotech NCT06841185
Ph3 A Clinical Trial Assessing the Safety and Efficacy of Biodegrad…unclassified InnoBM Pharmaceuticals Co… NCT06779461
Ph2+Ph3 QL1706, Bevacizumab, Oxaliplatin injectionunclassified Qilu Pharmaceutical Co., … NCT05976568
Ph2 RBS2418, STRIDE (durvalumab + tremelimumab)unclassified Riboscience, LLC. NCT07175441
Ph1+Ph2 GNOS-PV02, INO-9012, Pembrolizumabunclassified Geneos Therapeutics NCT04251117
Ph2 A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate …unclassified TaiRx, Inc. NCT07521852
Ph1+Ph2 WGI-0301, WGI-0301, Lenvatinbunclassified Zhejiang Haichang Biotech… NCT07540832
Ph1+Ph2 Autologous dual-target CAR-T cells selected from the predefined…unclassified Beijing Biotech NCT07523529
Ph2 Casdozokitug, Toripalimab, Bevacizumabunclassified Coherus Oncology, Inc. NCT06679985
Ph2 Nivolumab Injection [Opdivo], CVM-1118unclassified TaiRx, Inc. NCT05257590
Ph2 RP2, Bevacizumab, Atezolizumabunclassified Replimune, Inc. NCT05733598
Ph1+Ph2 EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophospham…unclassified Beijing Biotech NCT07500220
Ph2 WGI-0301, Nivolumab (240 mg), WGI-0301unclassified Zhejiang Haichang Biotech… NCT07494435
Ph2 ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w, ABSK-0…unclassified Abbisko Therapeutics Co, … NCT05441475
Ph1+Ph2 Armored and GPC3-targeted autologous CAR T-cellunclassified Shanghai AbelZeta Ltd. NCT06590246
Ph2 BB102unclassified Broadenbio Ltd., Co. NCT07239986
Ph2 GKL-006unclassified Beijing Gene Key Life Tec… NCT07209813
Ph2 BL-B01D1, Lenvatinib, Finotonlimabunclassified Sichuan Baili Pharmaceuti… NCT06986785
Ph2 LioCyx-M, Lenvatinibunclassified Lion TCR Pte. Ltd. NCT05195294
Ph1+Ph2 Placebo, FB-1603unclassified Febico Biomedical Corp. NCT06478719
Ph2 ZG005 for Injection, Bevacizumab, Sintilimabunclassified Suzhou Zelgen Biopharmace… NCT06558227
Ph1+Ph2 BC3402 injection, Durvalumab injectionunclassified Biocity Biopharmaceutics … NCT06111326
Ph2 A Study Evaluating the Safety and Efficacy of Selective Interna…unclassified Sirtex Medical NCT07663487
Ph1 HLX13, Yervoy, OPDIVOunclassified Shanghai Henlius Biotech NCT07176650
Drugs in this landscape: Lenvatinib · Bevacizumab · Durvalumab · Nivolumab · Nivolumab Injectable Product

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
AstraZeneca 12 2 1
Akeso 6 5 0
Roche 5 11 1
Shanghai Henlius Biotech 4 0 1
Exelixis 4 1 0
AbbVie 4 0 0
Bristol-Myers Squibb 3 10 3
Lion TCR Pte. Ltd. 3 1 1
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 3 0 0
Zhejiang Haichang Biotech Co., Ltd. 3 0 0
Abbisko Therapeutics Co, Ltd 3 0 0
Nanjing Sanhome Pharmaceutical, Co., Ltd. 3 0 0
Jiangsu HengRui Medicine Co., Ltd. 2 7 1
Boston Scientific Corporation 2 0 2
Eureka Therapeutics Inc. 2 0 2

All 15 active Hepatocellular Carcinoma sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2025 (157 registered). The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (132 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
55
2017
58
2018
67
2019
72
2020
69
2021
89
2022
99
2023
109
2024
127
2025
157
2026
99

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (12)
214
2017 (6)
452
2018 (8)
552
2019 (12)
528
2020 (8)
305
2021 (14)
240
2022 (11)
300
2023 (19)
214
2024 (12)
267
2025 (17)
228
2026 (13)
226

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT03017326 ACTIVE NOT RECRUITING
Paediatric Hepatic International Tumour Trial
University of Birmingham n=450
NCT06921785 RECRUITING
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
AstraZeneca n=1,220
NCT03186898 ACTIVE NOT RECRUITING
Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer
NRG Oncology n=115
NCT07166406 RECRUITING
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology n=226
NCT06618664 RECRUITING
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=590
NCT07322848 RECRUITING
DEB-TACE vs cTACE in HCC After TIPS
First Affiliated Hospital, Sun Yat-Sen University n=206
NCT05883644 ACTIVE NOT RECRUITING
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
AstraZeneca n=111
NCT04712643 ACTIVE NOT RECRUITING
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
Hoffmann-La Roche n=342
NCT07537946 NOT YET RECRUITING
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Tongji Hospital n=400
NCT07490262 RECRUITING
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. n=680
NCT03778957 ACTIVE NOT RECRUITING
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
AstraZeneca n=724
NCT06485466 RECRUITING
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
Guohui Xu n=101
NCT07293468 RECRUITING
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
Tuen Mun Hospital n=106
NCT05016245 ACTIVE NOT RECRUITING
MANDARIN (S6371)
Boston Scientific Corporation n=92
NCT05301842 ACTIVE NOT RECRUITING
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
AstraZeneca n=760
NCT04039607 ACTIVE NOT RECRUITING
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb n=732
NCT03298451 ACTIVE NOT RECRUITING
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
AstraZeneca n=1,324
NCT07475026 NOT YET RECRUITING
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
Tianjin Medical University Cancer Institute and Hospital n=198
NCT07461675 NOT YET RECRUITING
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
University of Geneva, Switzerland n=30
NCT03847428 ACTIVE NOT RECRUITING
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
AstraZeneca n=908
NCT07302919 RECRUITING
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
University Hospital, Basel, Switzerland n=152
NCT07417397 RECRUITING
Adjuvant TACE in HCC With High-risk Recurrence Factors
Guangxi Medical University n=442
NCT04770896 ACTIVE NOT RECRUITING
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
Hoffmann-La Roche n=557
NCT07392866 NOT YET RECRUITING
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Nanjing Sanhome Pharmaceutical, Co., Ltd. n=120
NCT06904170 RECRUITING
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
UNICANCER n=196
NCT07381660 NOT YET RECRUITING
SBRT Versus Surgical Resection for Small HCC
Sun Yat-sen University n=312
NCT05198609 ACTIVE NOT RECRUITING
Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Sun Yat-sen University n=214
NCT07356037 NOT YET RECRUITING
Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
Changchun GeneScience Pharmaceutical Co., Ltd. n=68
NCT07300488 ACTIVE NOT RECRUITING
Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma
Xi'an Xintong Pharmaceutical Research Co.,Ltd. n=60
NCT05904886 ACTIVE NOT RECRUITING
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
Hoffmann-La Roche n=687
NCT07309419 NOT YET RECRUITING
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital n=222
NCT04639180 ACTIVE NOT RECRUITING
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Jiangsu HengRui Medicine Co., Ltd. n=687
NCT03533582 ACTIVE NOT RECRUITING
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Children's Oncology Group n=537
NCT05317819 RECRUITING
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Polaris Group n=300
NCT07285850 RECRUITING
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
Eastern Hepatobiliary Surgery Hospital n=20
NCT07267806 RECRUITING
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
Linhui Peng n=326
NCT04194775 ACTIVE NOT RECRUITING
A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
CStone Pharmaceuticals n=534
NCT05320692 ACTIVE NOT RECRUITING
A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma
Jiangsu HengRui Medicine Co., Ltd. n=423
NCT03755791 ACTIVE NOT RECRUITING
Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy
Exelixis n=837
NCT04523493 ACTIVE NOT RECRUITING
Phase III Study of Toripalimab（JS001��� Combined With Lenvatinib for Advanced HCC
Shanghai Junshi Bioscience Co., Ltd. n=530
NCT06851663 RECRUITING
Trop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital n=400
NCT06172205 RECRUITING
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University n=262
NCT03383458 ACTIVE NOT RECRUITING
A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Bristol-Myers Squibb n=545
NCT06007846 RECRUITING
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
Inova Health Care Services n=12
NCT06644937 RECRUITING
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
Zhujiang Hospital n=30
NCT07186621 RECRUITING
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=286
NCT06680258 NOT YET RECRUITING
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Tempest Therapeutics n=740
NCT06109272 RECRUITING
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
AbbVie n=660
NCT06841172 RECRUITING
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
Shandong Cancer Hospital and Institute n=132
NCT02523443 ACTIVE NOT RECRUITING
Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection
Memorial Sloan Kettering Cancer Center n=231
NCT07027436 NOT YET RECRUITING
Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.
Hamilton Health Sciences Corporation n=30
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT05482516 RECRUITING
Evaluating Novel Therapies in ctDNA Positive GI Cancers
Georgetown University n=20
NCT06900543 ACTIVE NOT RECRUITING
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
Chengdu New Radiomedicine Technology Co. LTD. n=108
NCT04521153 ACTIVE NOT RECRUITING
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Shanghai Zhongshan Hospital n=294
NCT05201404 RECRUITING
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Can-Fite BioPharma n=471
NCT06844357 RECRUITING
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Zhejiang Raygene Pharmaceuticals Co., Ltd n=300
NCT05489289 RECRUITING
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Akeso n=570
NCT06371157 RECRUITING
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
Akeso n=469
NCT03895359 RECRUITING
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's n=128
NCT06841185 NOT YET RECRUITING
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
Shanghai Henlius Biotech n=656
NCT04344158 ACTIVE NOT RECRUITING
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=648
NCT06796803 NOT YET RECRUITING
Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
Shanghai Zhongshan Hospital n=398
NCT05557838 ACTIVE NOT RECRUITING
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
AstraZeneca n=214
NCT06492395 RECRUITING
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
Second Affiliated Hospital of Guangzhou Medical University n=178
NCT06779461 NOT YET RECRUITING
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
InnoBM Pharmaceuticals Co., Ltd. n=228
NCT04803994 RECRUITING
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest n=434
NCT05613478 RECRUITING
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University n=130
NCT06739317 NOT YET RECRUITING
SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Sun Yat-sen University n=398
NCT05744219 RECRUITING
Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial
Jon Unosson n=338
NCT06041477 RECRUITING
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
Sun Yat-sen University n=540
NCT04868149 RECRUITING
Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS
The University of Hong Kong n=40
NCT05594927 RECRUITING
Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
Beijing Shenogen Biomedical Co., Ltd n=261
NCT06478108 RECRUITING
Interventional Software for Multi-immunotherapy of Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University n=60
NCT03949231 RECRUITING
Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University n=200
NCT06434753 RECRUITING
Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
Hospital Universitari Vall d'Hebron Research Institute n=300
NCT06089369 NOT YET RECRUITING
Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
Tongji Hospital n=360
NCT05738616 RECRUITING
Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
Wen Tianfu n=196
NCT06201065 RECRUITING
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Sun Yat-sen University n=200
NCT06089382 NOT YET RECRUITING
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
Tongji Hospital n=104
NCT05985798 RECRUITING
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
Second Affiliated Hospital of Guangzhou Medical University n=258
NCT05976568 NOT YET RECRUITING
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Qilu Pharmaceutical Co., Ltd. n=668
NCT05608200 RECRUITING
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Second Affiliated Hospital of Guangzhou Medical University n=427
NCT05862337 RECRUITING
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. n=480
NCT05408221 RECRUITING
the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
Shandong New Time Pharmaceutical Co., LTD n=576
NCT05718232 NOT YET RECRUITING
SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
Sun Yat-sen University n=136
NCT05476432 RECRUITING
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
Sun Yat-sen University n=300
NCT05608213 RECRUITING
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
Second Affiliated Hospital of Guangzhou Medical University n=187
NCT04595864 RECRUITING
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School n=40
NCT03368651 RECRUITING
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
Sun Yat-sen University n=230
NCT07594340 RECRUITING
HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
Binkui Li n=300
NCT07589244 RECRUITING
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
Guangzhou Virotech Pharmaceutical Co., Ltd. n=66
NCT07620574 NOT YET RECRUITING
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis n=5,000
NCT03867084 COMPLETED
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
Merck Sharp & Dohme LLC n=959
NCT04246177 COMPLETED
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
Merck Sharp & Dohme LLC n=479
NCT02771405 COMPLETED
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
National Hepatology & Tropical Medicine Research Institute n=150
NCT02435953 COMPLETED
TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma
Ming Zhao n=241
NCT04102098 COMPLETED
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
Hoffmann-La Roche n=668
NCT04720716 COMPLETED
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd. n=344
NCT04777851 TERMINATED
Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7
Translational Research in Oncology n=45
NCT05665348 COMPLETED
Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
Federation Francophone de Cancerologie Digestive n=229
NCT01903694 COMPLETED
Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma
Centre Hospitalier Universitaire Dijon n=474
NCT03713593 COMPLETED
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Merck Sharp & Dohme LLC n=794
NCT01730937 COMPLETED
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Radiation Therapy Oncology Group n=193
NCT05153785 COMPLETED
Perioperative Intravenous Lidocaine in Liver Surgery
Lund University Hospital n=124
NCT05171166 TERMINATED
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
Peking University n=18
NCT04157985 COMPLETED
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Dan Zandberg n=161
NCT05033522 SUSPENDED
Immunotherapy for Advanced Liver Cancer
Mirror Biologics, Inc. n=150
NCT03412773 COMPLETED
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene n=684
NCT02799212 COMPLETED
Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma
Hospices Civils de Lyon n=179
NCT03062358 COMPLETED
Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)
Merck Sharp & Dohme LLC n=453
NCT04487067 COMPLETED
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
Hoffmann-La Roche n=152
NCT04732286 TERMINATED
A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy
Hoffmann-La Roche n=100
NCT02764801 COMPLETED
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University n=131
NCT04268888 SUSPENDED
Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
The Clatterbridge Cancer Centre NHS Foundation Trust n=522
NCT04709380 TERMINATED
Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=36
NCT02576509 COMPLETED
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb n=743
NCT02349412 COMPLETED
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology n=405
NCT01906216 COMPLETED
Sorafenib Chemoembolization Evaluation Controlled Trial
Air Force Military Medical University, China n=199
NCT03960008 TERMINATED
Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
Lahey Clinic n=9
NCT02112656 COMPLETED
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Imunon n=554
NCT02856126 COMPLETED
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
Sun Yat-sen University n=214
NCT04047173 COMPLETED
RFA Versus SBRT for Recurrent Small HCC
Sun Yat-sen University n=166
NCT02109146 COMPLETED
Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma
Zhejiang University n=332
NCT00617981 COMPLETED
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Imunon n=701
NCT02762266 TERMINATED
Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization
Stanford University n=13
NCT04103398 COMPLETED
TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma
Sun Yat-sen University n=162
NCT03764293 COMPLETED
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
Jiangsu HengRui Medicine Co., Ltd. n=543
NCT02650271 COMPLETED
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
Guangxi Medical University n=240
NCT02649153 COMPLETED
Effect of Smoked Plum and Chewing Gum on Postoperative Bowel Function Following Hepatic Resection
Guangxi Medical University n=240
NCT02329860 COMPLETED
Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)
Jiangsu HengRui Medicine Co., Ltd. n=400
NCT01004978 COMPLETED
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI) n=235
NCT00716976 COMPLETED
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Children's Oncology Group n=131
NCT03434379 COMPLETED
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Hoffmann-La Roche n=558
NCT00658593 TERMINATED
Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer
NCIC Clinical Trials Group n=19
NCT00699816 COMPLETED
Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
GC Cell Corporation n=230
NCT02973685 COMPLETED
HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.
Sun Yat-sen University n=315
NCT05564338 WITHDRAWN
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
BeiGene
NCT03236649 TERMINATED
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
Beijing Shenogen Biomedical Co., Ltd n=89
NCT02438436 COMPLETED
Simo Decoction and Gum Chewing for Bowel Activity
Guangxi Medical University n=180
NCT02435433 COMPLETED
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Eli Lilly and Company n=399
NCT02702401 COMPLETED
Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)
Merck Sharp & Dohme LLC n=413
NCT04985136 TERMINATED
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
Jiangsu HengRui Medicine Co., Ltd. n=1
NCT01015833 COMPLETED
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI) n=356
NCT01402908 TERMINATED
A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
Cellxpert Biotechnology Corp. n=520
NCT04465734 WITHDRAWN
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
NCT01761266 COMPLETED
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Eisai Limited n=954
NCT01164202 COMPLETED
Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer
Federation Francophone de Cancerologie Digestive n=78
NCT01387932 TERMINATED
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
Merit Medical Systems, Inc. n=235
NCT01655693 COMPLETED
Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma
Valerio Therapeutics n=397
NCT01908426 COMPLETED
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Exelixis n=707
NCT01887717 TERMINATED
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
Boston Scientific Corporation n=36
NCT01755767 COMPLETED
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
Daiichi Sankyo n=383
NCT02851784 COMPLETED
Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
Chinese PLA General Hospital n=40
NCT02460991 TERMINATED
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
Boston Scientific Corporation n=2
NCT03164382 COMPLETED
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
Sun Yat-sen University n=262
NCT02562755 COMPLETED
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
SillaJen, Inc. n=459
NCT04546802 WITHDRAWN
HepATocellular Cancer Hcv Therapy Study
Bayside Health
NCT01774344 COMPLETED
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Bayer n=573
NCT01075555 COMPLETED
Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
Federation Francophone de Cancerologie Digestive n=323
NCT03990974 SUSPENDED
Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection
Sun Yat-sen University n=458
NCT01438476 COMPLETED
Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas
M.D. Anderson Cancer Center n=178
NCT02867280 TERMINATED
Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection
Sun Yat-sen University n=154
NCT01833299 COMPLETED
Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma
Sun Yat-sen University n=120
NCT02645981 COMPLETED
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd n=668
NCT04044651 WITHDRAWN
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
Shi Ming
NCT02774187 COMPLETED
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
Sun Yat-sen University n=247
NCT00908752 COMPLETED
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
Bristol-Myers Squibb n=734
NCT00825955 COMPLETED
Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment
Bristol-Myers Squibb n=587
NCT01287585 COMPLETED
Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy
Polaris Group n=636
NCT03059238 COMPLETED
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
Sun Yat-sen University n=213
NCT01465464 TERMINATED
Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma
Taiho Pharmaceutical Co., Ltd. n=888
NCT02584556 WITHDRAWN
Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma
Guangxi Medical University
NCT02527772 WITHDRAWN
Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Guangxi Medical University
NCT02534337 WITHDRAWN
Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma
Guangxi Medical University
NCT02585479 WITHDRAWN
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
Guangxi Medical University
NCT00901901 COMPLETED
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Bayer n=732
NCT03791918 WITHDRAWN
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sun Yat-sen University
NCT03744247 WITHDRAWN
Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
Sun Yat-sen University
NCT01676194 TERMINATED
Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma
Rennes University Hospital n=7
NCT01259414 COMPLETED
Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma
Sun Yat-sen University n=812
NCT01229839 COMPLETED
Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC
Sun Yat-sen University n=668
NCT02220088 TERMINATED
The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial
Sun Yat-sen University n=79
NCT03636620 COMPLETED
TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial
Fudan University n=110
NCT00692770 COMPLETED
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Bayer n=1,114
NCT02971696 COMPLETED
Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.
Ain Shams University n=55
NCT02149771 WITHDRAWN
Combination Treatment for Advanced Liver Cancer
Shanghai Zhongshan Hospital
NCT01829035 COMPLETED
A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC
National Cancer Center, Korea n=339
NCT01932385 COMPLETED
Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma
Qingdao Central Hospital n=86
NCT01265810 COMPLETED
Caphosol in Oral Mucositis Due to Targeted Therapy
Impaqtt Foundation n=64
NCT01596283 COMPLETED
Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Liver Resection
Memorial Sloan Kettering Cancer Center n=135
NCT02029157 COMPLETED
A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)
Kyowa Kirin Co., Ltd. n=386
NCT01901692 COMPLETED
Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion
Asan Medical Center n=90
NCT02829359 COMPLETED
Effects of Antiviral Therapy on HBV Reactivation
Guangxi Medical University n=200
NCT01405573 TERMINATED
Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma
National Cancer Institute, Naples n=35
NCT01804829 COMPLETED
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
Biotest Pharmaceuticals Corporation n=80
NCT01313377 COMPLETED
Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
UNICANCER n=190
NCT02319200 TERMINATED
Primary Prevention Hepatocellular Carcinoma by Metformin
Assistance Publique - Hôpitaux de Paris n=11
NCT00858871 COMPLETED
First Line Hepato Cellular Carcinoma (HCC)
Bristol-Myers Squibb n=1,714
NCT02788526 COMPLETED
Adjuvant TACE to Reduce the HCC Recurrence After Resection
Sun Yat-sen University n=180
NCT01964001 COMPLETED
The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer
Taichung Veterans General Hospital n=71
NCT02004210 WITHDRAWN
A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma
Seoul National University Hospital
NCT00769106 COMPLETED
Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer
Sun Yat-sen University n=200
NCT01749865 COMPLETED
CIK Treatment for HCC Patient Underwent Radical Resection
Sun Yat-sen University n=200
NCT00820339 COMPLETED
Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy
Eastern Hepatobiliary Surgery Hospital n=132
NCT00814242 COMPLETED
Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels
Eastern Hepatobiliary Surgery Hospital n=120
NCT00827554 COMPLETED
The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma
Eastern Hepatobiliary Surgery Hospital n=100
NCT01140347 COMPLETED
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib
Eli Lilly and Company n=565
NCT01108705 TERMINATED
Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
Bristol-Myers Squibb n=87
NCT00902343 COMPLETED
Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection
Memorial Sloan Kettering Cancer Center n=149
NCT01872988 TERMINATED
Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma
Taichung Veterans General Hospital n=320
NCT02038296 COMPLETED
Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma
Guangdong Provincial People's Hospital n=162
NCT00699374 TERMINATED
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
Pfizer n=1,075
NCT01009593 TERMINATED
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott n=1,035
NCT01327521 WITHDRAWN
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Albert Koong
NCT01318200 WITHDRAWN
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)
Accuray Incorporated

Full Hepatocellular Carcinoma Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Frequently asked

Common questions about the Hepatocellular Carcinoma landscape

How many companies are developing Hepatocellular Carcinoma treatments?
14 companies have active or registered Hepatocellular Carcinoma programs in TheraRadar's competitive landscape (98 classified trials). The most active are AstraZeneca, Roche / Genentech, and Akeso.
What mechanisms of action are being developed for Hepatocellular Carcinoma?
15 distinct mechanisms of action appear across the Hepatocellular Carcinoma pipeline, including Multikinase (VEGFR), Anti-VEGF (bevacizumab), CTLA-4, VEGFA, and GARP:TGF-β1 complex antibody.
What is the most crowded mechanism in Hepatocellular Carcinoma?
Multikinase (VEGFR) is the most contested mechanism in Hepatocellular Carcinoma, with 7 programs mapped to it.
Are there upcoming Hepatocellular Carcinoma clinical readouts or FDA decisions?
Near-term Hepatocellular Carcinoma catalysts include Lenvatinib (data readout, Jun '26); Sorafenib (data readout, Jul '26); Camrelizumab (FDA decision, Jul '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.
Where does TheraRadar's Hepatocellular Carcinoma landscape data come from?
Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.
Is the Hepatocellular Carcinoma heatmap free to use?
Yes — viewing and searching the Hepatocellular Carcinoma heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.
How this is built — methodology & limits

These grids are only as good as the data and the classification behind them — so here is exactly what goes in, what stays out, how every assignment is made, and where the limits are.

Where the data comes from

Every heatmap is built from the public ClinicalTrials.gov registry, via its official API — interventional drug and biologic trials with a start date of 2008 or later. The master index holds over 145,000 trials and is refreshed weekly (see the “updated” date on this page). A disease landscape draws only from the active, Phase 1–3, industry-sponsored slice of that index.

  • In scope: industry-sponsored trials in Phase 1, 2, or 3, with an active status (recruiting, active-not-recruiting, not-yet-recruiting, or enrolling by invitation). Phase 4 sits in the index but is left out of the landscapes.
  • Filtered out: deeply stale programs (a primary completion date more than two years past with no update to completed or terminated); basket trials and incidental mentions (a trial counts toward a disease only when that disease is genuinely the subject of study — not a secondary cohort, an organ-of-origin overlap, or a passing mention); and healthy-volunteer studies.

We do not exclude trials by sponsor geography. Where a sponsor is based in China, the program is flagged on the page rather than hidden, so you can weigh it yourself. An automated test fails the weekly refresh if the underlying index is more than 14 days old, so a published grid is never built on a stale index.

How a trial is matched to a disease

Matching uses a structured medical ontology, not keyword guessing, and is designed so that no trial is ever silently dropped — every trial that clears the filters gets a classification, even if that is just “Other.” It runs as an ordered sequence of steps, stopping at the first that applies:

  1. Healthy-volunteer studies are set aside as non-disease trials.
  2. Ontology match — each tracked disease is linked to its official identifiers in the standard medical taxonomy (MeSH), so a trial can be matched even when its text uses a synonym.
  3. Curated disease patterns — a hand-maintained library of over 150 disease-name patterns covers the more granular indications across oncology, hematology, infectious disease, cardiometabolic, immunology, and neuropsychiatry.
  4. Basket guard — a trial matching four or more distinct diseases, or carrying explicit basket language (“tumor-agnostic,” “all solid tumors,” “pan-cancer”), is grouped into a single advanced-solid-tumor category rather than over-counted across every cancer it touches.
  5. Therapeutic-area roll-up — a trial with no specific match, but which the taxonomy still places under a broad area, is assigned to that area (“Oncology — other,” “Immunology — other,” …), checking cancers first so a site-specific tumor isn’t filed under its anatomical system.

A “drop-if-parent-present” rule keeps a generic name from drowning out a subtype: a trial matching both lupus and lupus nephritis is reported only as lupus nephritis. Internal abbreviations are translated to the plain disease names used across the site (for example, “CRC” becomes “Colorectal Cancer”), and the same classifier is shared by every heatmap, so the same trial always maps to the same disease wherever it appears.

How a drug is matched to its mechanism

Mechanism of action is the hardest part to get right, so it is assigned in layers — leaning on curated and public data first, with AI as a last resort:

  1. Curated rulebook (first). A rulebook we maintain — over 600 drug-to-mechanism rules — is checked first, matching on drug names, trial acronyms, sponsor trial identifiers, and intervention lists. First match wins, which stops a combination trial from being counted several times.
  2. Public molecular-target data. Where no rule applies, each intervention’s target is looked up in a public target database, with verbose or gene-symbol labels normalized into consistent short forms so one target isn’t split across several columns.
  3. Standard-of-care backbones. A small set of rules recognizes common combination scaffolds (checkpoint-inhibitor monotherapy, standard chemotherapy regimens, established standard-of-care agents) so they aren’t mistaken for the experimental arm.
  4. AI as a last resort, then cross-checked. Only for genuinely opaque sponsor code-names that none of the first three steps can resolve do we ask an AI model to propose a mechanism — applied only above a fixed confidence bar, then automatically cross-checked against the sponsor’s own pipeline page. Where AI and the sponsor agree, the program is marked sponsor-verified. Where they contradict, the label is discarded entirely — not shown, not counted.

New mechanism rules are independently double-verified before they’re trusted — a second, adversarial pass set up to disprove the first — and each is checked so it can’t mislabel an unrelated trial. Drugs whose mechanism isn’t publicly disclosed are shown openly as “Emerging — not yet disclosed” rather than guessed at: for a tool meant to support real decisions, “we don’t yet know” is a more trustworthy answer than a confident guess.

Where AI is used — and where it isn’t

The disease and mechanism matching above is driven first by deterministic rules and public ontologies, not AI. AI plays three bounded, disclosed roles: (1) an optional extra check that a trial genuinely studies the disease, on top of the ontology match; (2) inferring a trial’s treatment setting on the competitive grids when the rules don’t cover it, only above a fixed confidence bar; and (3) the last-resort mechanism step above, always cross-checked against the sponsor’s disclosures. Wherever an AI label reaches a cell, the page marks it (⚙️ or ✅) — AI is never the silent, sole source of what you see.

What the on-page markers mean

  • ✅ Sponsor-verified — AI proposed the mechanism and it matched the sponsor’s own pipeline page. High-trust.
  • ⚙️ AI-classified — AI proposed it above the confidence bar but it has not yet been cross-checked against the sponsor. Useful; verify before citing. It never means a person reviewed it.
  • ⚡ First-in-class — the mechanism hasn’t appeared in any other disease landscape we’ve built. This reflects the scope of landscapes published so far (the tooltip lists exactly which were scanned), not an absolute claim about the whole market.
  • 🌱 First-in-indication — the only program competing on that mechanism within this disease.
  • 🆕 NME candidate — the interventions match no drug in our approved-drug index, suggesting a new molecular entity. The index is incomplete — a signal, not a regulatory fact.
  • 🔗 Combination · 👶 Pediatric · 🔥 Hot (readout within six months) · ⏳ Stale (completion date passed but still marked active — often a stalled program).

Sponsor names are resolved through a curated parent/subsidiary map; unrecognized sponsors appear under their raw registry name. The registry records the sponsor at a trial’s inception, so names are as originally filed and may not reflect later acquisitions. To keep large grids legible, mechanisms with a single program are listed separately rather than crowding the main grid, and very small players are listed below it — presentation choices only; nothing is removed from the underlying counts.

How we score programs — “what’s about to move”

Each program carries a 0–100 score that deliberately ranks imminence over raw stage — the most decision-relevant signal on a competitive grid. It is the sum of:

  • Clinical phase — up to 40 points (Phase 3 = 40, Phase 2 = 25, Phase 1 = 10).
  • Readout proximity — up to 60 points (next readout <6 months = 60, 6–12 months = 45, 1–2 years = 30, distant = 5).
  • Stale penalty — the score is halved if a trial is past its expected readout but still listed as active.

Cell colour on the grid is driven by this score, so a Phase 2 program about to read out can — correctly — outrank a dormant Phase 3 one. It answers “what’s about to move,” not just “what’s furthest along.”

What each grid plots

  • Indication landscape (this page) — one disease — companies (rows) × mechanism of action (columns): who is competing, and on what mechanism.
  • Company portfolio — one company — diseases (rows) × mechanism (columns): where it is active, and what it is betting on.
  • MOA platform — one mechanism family — drugs (rows) × diseases (columns): who is working on this class, and where.
  • Competitive landscape — one disease — mechanism (rows) × clinical setting (columns), aggregated across companies; setting columns are tailored per disease (e.g. lines of therapy in oncology; biologic-naïve vs. biologic-experienced in IBD).

What we don’t claim

  • First-in-class is editorial, not absolute — “not seen in the landscapes we’ve built,” not “novel across the industry.”
  • NME candidate is a signal, not a filing — absent from our (incomplete) approved-drug index.
  • Disease matching is automated and not exhaustively validated per disease — ontology and pattern matching can occasionally include or miss a trial.
  • AI-classified mechanisms are machine-proposed — unconfirmed unless they also carry ✅.
  • Sponsor names are as-filed and may lag current ownership.
  • Grids are as fresh as their last rebuild from the weekly index — no faster continuous refresh is claimed.

Data: ClinicalTrials.gov v2 API + FDA Drugs@FDA (approved-drug index). Spot an error? [email protected].

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only